STOCK TITAN

Geron Corp - GERN STOCK NEWS

Welcome to our dedicated page for Geron news (Ticker: GERN), a resource for investors and traders seeking the latest updates and insights on Geron stock.

Geron Corporation (GERN) is a clinical-stage biopharmaceutical company advancing novel oncology therapies through its telomerase inhibitor research. This page provides investors and industry professionals with verified updates on clinical developments, regulatory milestones, and strategic initiatives.

Access the latest press releases and analysis related to imetelstat's progress in treating hematologic malignancies like myelodysplastic syndromes. Our curated collection ensures you stay informed about trial results, partnership announcements, and scientific presentations without speculative commentary.

Key updates include details on Phase 3 clinical trials, FDA communications, intellectual property developments, and collaboration agreements. All content is sourced directly from official company channels to maintain accuracy and compliance.

Bookmark this page for streamlined access to Geron's evolving story in cancer therapeutics. Check back regularly for objective reporting on advancements in telomerase-targeted treatment approaches.

Rhea-AI Summary
Geron's NDA for imetelstat accepted by FDA for the treatment of anemia in MDS patients. Positive efficacy results and significant increase in hemoglobin levels. Expectation of changing standard of care in lower risk MDS. Safety consistent with prior clinical experience. FDA has up to 74 days to notify PDUFA action date. MAA submission in EU expected in Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.77%
Tags
-
Rhea-AI Summary
Geron Corporation has granted non-statutory stock options to newly hired employees, totaling 189,850 shares. The options were granted at an exercise price of $2.70 per share and have a 10-year term. Some options vest over four years, while others vest upon achievement of a regulatory milestone.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.35%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.33%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.65%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.29%
Tags
none
-
Rhea-AI Summary
Geron Corporation announces availability of Expanded Access Protocol for imetelstat, a telomerase inhibitor for lower risk myelodysplastic syndromes (MDS). Positive IMerge Phase 3 results submitted to FDA. NDA also submitted.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.96%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.28%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.65%
Tags
conferences
Geron Corp

Nasdaq:GERN

GERN Rankings

GERN Stock Data

808.88M
632.77M
0.1%
78.42%
9.17%
Biotechnology
Pharmaceutical Preparations
Link
United States
FOSTER CITY